BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF

Executive Summary

• BioNxt Solutions has engaged a Business Development & Licensing (BD&L) specialist advisor to advance the commercialization, partnering, and licensing strategy for its patented sublingual Cladribine ODF program (BNT23001) for multiple sclerosis.
• The company is preparing for a planned human bioavailability study designed to compare its 10 mg ODF formulation against the approved reference product Mavenclad® 10 mg tablets.
• The strategic initiative focuses on identifying pharmaceutical partners, evaluating transaction structures, and positioning BNT23001 for potential co-development or commercialization agreements.

Key Details

• Advisor Engagement: BioNxt has commenced work with a BD&L specialist to refine commercial positioning, identify potential pharma partners, evaluate transaction structures, and prepare for business development engagement.
• Product Profile: BNT23001 is a patented proprietary sublingual Cladribine orally dissolvable film (ODF) formulated as a differentiated alternative to conventional tablet-based Cladribine therapy, specifically targeting MS patients with dysphagia.
• Market Context: The reference product, Mavenclad® (developed by Merck KGaA), reported approximately €1.2 billion / US$1.4 billion in global revenues in 2025, reflecting continued growth and strong demand across North America and Europe.
• Planned Clinical Study: A human bioavailability study is in preparation to compare Cladribine ODF 10 mg with Mavenclad® 10 mg tablets.
• Study Objectives: The study will assess key pharmacokinetic parameters including total drug exposure, peak plasma concentration, and time to peak concentration, while monitoring safety and tolerability.
• Next Steps & Disclaimer: BioNxt will develop partnering materials, analyze comparable transactions, assess priority territories, and evaluate deal structures. The company explicitly states there is no assurance that the advisor engagement or strategic evaluation will result in a licensing, co-development, commercialization, or other business arrangement.

Notable Quotes

• "Engaging a BD&L Advisor is an important step in the commercial planning process for our Cladribine ODF program," said Hugh Rogers, CEO and Co-Founder of BioNxt Solutions Inc. "As we prepare for the planned human bioavailability study, our strategy is to ensure that BNT23001 is positioned effectively for potential pharmaceutical partners."